Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 5
Submit an article Journal homepage
110
Views
0
CrossRef citations to date
0
Altmetric
Comments

Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement

Adrian Minsona Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, AustraliaCorrespondence[email protected]
View further author information
&
Michael Dickinsona Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia;b Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, AustraliaView further author information
Pages 546-547 | Received 13 Feb 2024, Accepted 14 Feb 2024, Published online: 29 Feb 2024

References

  • Gribbin C, Chen J, Martin P, et al. Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond. Leuk Lymphoma. 2024;65(1):1–13. doi:10.1080/10428194.2023.2264430
  • McLaughlin N, Wang Y, Witzig T, et al. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023;64(2):371–377. doi:10.1080/10428194.2022.2148211
  • Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma. 2024 Jan 22:1–5. doi: 10.1080/10428194.2024.2304622. Epub ahead of print. PMID: 38248629.
  • Wang M, Munoz J, Goy A, et al. Three-Year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-Risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–567. doi:10.1200/JCO.21.02370
  • Wang M, Siddiqi T, Gordon LI, et al. Lisocabtagene maraleucel (liso‐cel) in R/R mcl: primary analysis results from the mcl cohort of the single‐arm, multicenter, seamless design transcend nhl 001 study. Hematol Oncol. 2023;41(S2):875–877. doi:10.1002/hon.3196_LBA3
  • Kambhampati S, Ahmed N, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis by prior treatment. J Clin Oncol. 2023;41(16_suppl):7507–7507. doi:10.1200/JCO.2023.41.16_suppl.7507
  • Nie EH, Su Y-J, Baird JH, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(12):3606–3610. doi:10.1182/bloodadvances.2021006922
  • Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-Care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594–2606. doi:10.1200/JCO.22.01797
  • Lewis KL, Cheah CY. Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with Central nervous system involvement: progress, but not perfect. Br J Haematol. 2023;203(5):701–703. doi:10.1111/bjh.19095
  • Munoz JL, Wang Y, Jain P, et al. BTK inhibitors and CAR T-cell therapy in treating mantle cell lymphoma-Finding a dancing partner. Curr Oncol Rep. 2022;24(10):1299–1311. doi:10.1007/s11912-022-01286-0
  • Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650–1660. doi:10.1182/blood.2019002936
  • Gill SI, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022;6(21):5774–5785. doi:10.1182/bloodadvances.2022007317
  • Ruella M, Kenderian SS, Shestova O, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684–2696. doi:10.1158/1078-0432.CCR-15-1527
  • Minson AG, Hamad N, Cheah CY, et al. CAR T-cells and time-Limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: phase II TARMAC study. Blood. 2024 Feb 22;143(8):673–684; doi:10.1182/blood.2023021306
  • Rusconi C, Cheah CY, Eyre TA, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with Central nervous system relapse. Blood. 2022;140(17):1907–1916. doi:10.1182/blood.2022015560

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.